

Press Release

April 17, 2019

For further information:

Peter Friedli
Chollerstrasse 35
6300 Zug
Tel: 041 740 25 25
Email: info@newventuretec.com

New Venturetec's Major Investment, Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc

Zug, April 17, 2019. New Venturetec's major investment, Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that it has completed the previously announced sale of Osiris to Smith & Nephew plc ("Smith & Nephew") through the consummation of a merger of Osiris with and into an indirect wholly-owned subsidiary of Smith & Nephew (the "Subsidiary") without a vote of the Osiris stockholders in accordance with Section 3-106.1 of the Maryland General Corporation Law. More than a majority of the outstanding shares of Osiris common stock were tendered in the tender offer. In the second-step merger, each share of Osiris common stock that was not purchased by Smith & Nephew in the tender offer (other than shares directly owned by the Subsidiary or by any subsidiary of Osiris) has been converted into the right to receive \$19.00 per share in cash, without interest, subject to any required withholding of taxes, which is the same cash price per share as was paid in the tender offer. As a result of the merger, Osiris became an indirect wholly-owned subsidiary of Smith & Nephew and Osiris' shares will cease to be traded on the NASDAQ Global Select Market.

New Venturetec did not tender its shares.

The Board of Directors of New Venturetec will call an extraordinary Shareholders' meeting for June 25, 2019, 09:00 a.m. in Zug. Details will follow.

About New Venturetec

New Venturetec is a publicly traded Swiss investment company (SIX: NEV) which holds participations in venture companies in the areas of biotechnology and technology which are domiciled in the USA.

The investment horizon should be 10 years or more. A shareholder is recommended to follow the development with interest and base an investment or disinvestment decision on results of the development of the portfolio companies rather than on the general capital market and the investors' sentiment. Any investor should only invest in New Venturetec if he can afford the complete loss of the investment without having to change his lifestyle. Significant risk is involved and the timelines may exceed the expectations. In addition, the market of New Venturetec shares is very illiquid. The risks of venture investments are 100%. The total loss of the investment has to be considered as a realistic possibility.